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ABSTRACT: 
 
 Human Germline Modification (HGM) involves the 
alteration of genes in a human subject, thereby creating changes 
to physical traits that can be passed on to the subject’s offspring.  
Recent developments in genetic engineering, including the 
discovery of the CRISPR/Cas9 gene editing tool, have made HGM 
a realistic possibility in the near future. Currently, HGM in the 
United States is regulated by a rider on the Appropriations Act 
that prevents federal funding from being used for FDA review of 
any treatment options involving HGM. The rider therefore 
precludes the clinical development of any potential treatment that 
utilizes HGM – even those designed to cure or prevent severe 
inheritable diseases. This paper reviews the current state of the 
science and law surrounding HGM, as well as the various ethical 
principles that underlie current U.S. and international policy.  
After careful consideration of these principles, this paper suggests 
a middle path forward for the development of HGM in the near 
future: an amendment to the current rider that allows the 
development of HGM therapies to treat severe genetic diseases that 
have no better alternative treatment. 
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I. INTRODUCTION 
 
 Until recently, the prospect of altering the genetics of our 
children has been speculative and remote, relegated to science 
fiction and theoretical debate. However, with the advent of new 
techniques in genetic engineering, mankind may soon have the 
ability to introduce targeted mutations during in vitro 
fertilization (IVF). These embryos may soon be implanted into a 
womb, where they will develop into a baby and eventually be born 
into this world: the first genetically engineered human beings in 
history. No longer merely hypothetical, reproduction using 
human germline modification (HGM)1 has become a pressing 
international policy issue with serious implications for the future 
of medicine.  
  This paper will begin by exploring various aspects of HGM 
in its present state: (1) relevant advances in scientific 
understanding and bioengineering technology; (2) the potential 
clinical applications of HGM; and (3) the current international 
and domestic landscape for regulation of HGM. In discussing 
domestic HGM regulation, an emphasis is placed on the U.S. rider 
on the 2016 Consolidated Appropriations Act that effectively 
prevents the clinical development of HGM in the U.S. 
Additionally, the legislative purpose of the rider will be discussed, 
highlighting specific ethical concerns that have guided U.S. 
policy. 
 Lastly, this paper will propose an amendment to the 
current rider, which would allow the development of HGM as a 
preventative therapy for severe genetic diseases. In making the 
case for this amendment, this paper will explore three policy 
options regarding the future of HGM for reproduction in the U.S.: 
(1) failure to renew the rider for the following year; (2) renewal of 
the rider in its intact form; and (3) adoption of the proposed 
amendment to the current rider. Allowing the clinical 
development of HGM for the treatment of severe monogenic 
diseases may prevent unnecessary pain and suffering, reduce the 
costs associated with these diseases, and ensure that the U.S. 
remains an ethical and responsible leader in the field of 
bioengineering. 
 
  
                                                          
1 Although HGM has potential research and development applications in many 
biomedical fields, the exclusive focus of this paper is the use of HGM for 
reproduction. 
16:1  SANTA CLARA JOURNAL OF INTERNATIONAL LAW   64 
II. BACKGROUND 
 
A. Genetic Diseases and Inheritance 
 
 Before discussing the potential applications of HGM, it is 
critical to understand some of the basic science underlying 
inherited diseases, which are typically caused by mutations in the 
DNA that are passed from parent to offspring.2 Mutations in the 
DNA may cause the production of defective proteins, which can 
lead to genetic diseases.3 As opposed to the proteins encoded by 
the wild-type gene4, these defective proteins either remain in the 
cell, unable to properly function, or are detected by the cell and 
destroyed.5 In either of these cases, the body is left unable to 
perform a basic, yet highly important process, leading to the 
symptoms of the disease.6 When a genetic disease is caused by 
mutations in a single gene, they are known as monogenic 
diseases, whereas those caused by the combined influence of 
multiple genes are polygenic.7 
 Like physical traits, genetic diseases can be inheritable.8 
This relationship is particularly evident in monogenic diseases. 
For example, in an autosomal dominant disorder such as 
Huntington’s disease, one chromosome carrying a mutated copy 
of the gene is enough to cause the disease.9 In this case, if one 
parent carries the mutation, there is a 50% chance of the child 
being affected by the disease. In an autosomal recessive disorder, 
both chromosomes must carry the afflicted gene. If both parents 
carry the gene but are otherwise healthy, the child has a 25% 
chance of being born with the disease. 10 For this reason, 
                                                          
2 See generally NEIL A. CAMPBELL & JANE B. REECE, BIOLOGY (Beth Wilbur et 
al. eds., 7th ed. 2005). 
3 See Campbell & Reece, supra note 2. 
4 Wild-type genes are typically defined as the gene that encodes for the 
phenotype that is the most common gene in a natural population. Here, it is 
used to refer to any gene that codes for a phenotype that naturally occurs in a 
substantial portion of the healthy population. 
5 See Peter Bross, et al., Protein misfolding and degradation in genetic 
diseases, 14 HUM. MUTATION 186 (Sep. 2, 1999), available at 
http://www.els.net/WileyCDA/ElsArticle/refId-a0006016.html.  
6 Id.  
7 See generally Campbell & Reece, supra note 2. 
8 See id.; see also U.S. Nat’l Library of Med., What are the different ways in 
which a genetic condition can be inherited?, NIH GENETICS HOME REFERENCE 
(Dec. 19, 2017), 
https://ghr.nlm.nih.gov/primer/inheritance/inheritancepatterns [hereinafter 
NIH Genetics].  
9 See NIH Genetics, supra note 8. 
10 Id. 
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autosomal recessive diseases do not always present themselves in 
every generation of a family.11 Diseases carried solely on the X or 
Y sex chromosomes are known as X-linked12 and Y-linked13 
diseases. In addition, some mitochondrial disorders are 
inheritable genetic conditions caused by mutations in the 
mitochondrial DNA.14 
  Although a monogenic disease is caused by a mutation in 
only one gene, the resulting disease may still be complex.15 For 
example, PKU is caused by a mutation that results in faulty PAH 
enzymes, which metabolize the amino acid phenylalanine.16 
However, symptoms of PKU are complex. They include heart 
problems, small head, and low birth weight.17 Different mutations 
on different parts of the gene can cause some symptoms of PKU 
to be more severe than others.18 Additionally, the severity of these 
symptoms are dependent on non-genetic, environmental factors, 
such as a patient’s diet.19 Polygenic diseases are even more 
complicated than monogenic diseases in both their symptoms and 
inheritance patterns.20 
 
B. Clinical Applications of Genomic Screening 
and Genetic Engineering 
 
Generally speaking, there are three primary methods for 
preventing inherited diseases at the stage of embryo formation 
using advanced IVF techniques: (1) preimplantation genetic 
diagnosis; (2) mitochondrial replacement therapy; and (3) human 
                                                          
11 Id. 
12 See id. (explaining that X-linked diseases are caused by mutations in genes 
on the X chromosome and can be also be both recessive and dominant. In X-
linked recessive diseases, the male children are more frequently affected 
because they only carry one X chromosome). 
13 Id.  
14 See NIH Genetics, supra note 8. 
15 See Charles R. Scriver & Paula J. Waters, Monogenic traits are not simple: 
lessons from phenylketonuria, 15 TRENDS IN GENETICS 267, 267-70 (Jul. 
1999), available at 
http://www.sciencedirect.com/science/article/pii/S0168952599017618. 
16 See id. 
17 Id. 
18 See Yoshiyuki Okano, et al., Molecular Basis of Phenotypic Heterogeneity in 
Phenylketonuria, 324 N. ENGLAND J. MED. 1232 (May 2, 1991), available at 
http://www.nejm.org/doi/full/10.1056/NEJM199105023241802#t=article.  
19 See Charles R. Scriver, supra note 15. 
20 See Kelly Frazer, et al., Human genetic variation and its contribution to 
complex traits, 10 NATURE REV. GENETICS 241 (April, 2009), available at 
http://www.nature.com/nrg/journal/v10/n4/full/nrg2554.html. 
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germline engineering. The basics of these three methods are 
discussed below. 
 
1. Pre-implantation Genetic Diagnosis 
 
 At the moment, some parents already attempt to avoid 
inheritable diseases by using a technique called preimplantation 
genetic diagnosis (PGD).21 PGD is accomplished by growing 
several embryos during the IVF process, removing a cell from 
each embryo or blastocyst, and sequencing each genome to assess 
which embryos carry the inheritable disease.22 Those that do not 
carry the disease are then implanted into the mother and brought 
to term.23 This practice is widely employed in countries across the 
world, including the U.S., to increase the chance that people 
afflicted with genetic diseases will have healthy offspring.24 
 
2. Mitochondrial Replacement Therapy 
 
 When the mutated gene causing the disease is located on 
the mitochondrial DNA (mtDNA) and not the nuclear DNA 
(nDNA), mitochondrial replacement therapy (MRT) might be able 
to prevent the passage of the disease to children.25 MRT is 
predominantly accomplished using one of two techniques, both of 
which involve the use of a donor’s mtDNA and the mother’s 
nDNA.26 As the donor’s mtDNA does not carry the affected gene, 
a child born from a successful MRT procedure should not develop 
the disease.27 However, MRT may result in inheritable changes 
                                                          
21 See ASRM Ethics Committee, Use of preimplantation genetic diagnosis for 
serious adult onset conditions: a committee opinion, 100 FERTILITY & 
STERILITY 54 (Jul. 2013), available at 
http://www.sciencedirect.com/science/article/pii/S0015028213003427.  
22 See Joyce C. Harper & Sioban B. Sengupta, Prelimplantation genetic 
diagnosis: State of the ART 2011, 131 HUMAN GENETICS 175 (Feb. 2012), 
available at http://link.springer.com/article/10.1007/s00439-011-1056-z.  
23 See id.  
24 See id. 
25 Klaus Reinhardt, et al., Mitochondrial Replacement, Evolution, and the 
Clinic, 341 SCIENCE 1345 (Sep. 20, 2013), available at 
http://science.sciencemag.org/content/341/6152/1345.full.  
26 First, protonuclear spindle involves the transfer of nuclear DNA from a 
fertilized zygote to an enucleated donor zygote. Alternatively, in maternal 
spindle transfer, the nuclear material of an unfertilized oocyte can be 
transferred to an enucleated donor oocyte. See P. Amato, et al., Three-parent 
in vitro fertilization: gene replacement for the prevention of inherited 
mitochondrial diseases, 101 FERTILITY & STERILITY 31, 32 (Jan. 2014), 
available at https://www.ncbi.nlm.nih.gov/pubmed/24382342.   
27 Reinhardt, et al., supra note 25. 
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to DNA, particularly in female offspring.28 Because MRT has the 
potential to create inheritable genetic changes, its use has been 
controversial.29 Nevertheless, the United Kingdom has recently 
become the first country to permit the clinical evaluation of 
MRT.30 
 
a. Somatic Cell Engineering and Human 
Germline Modification 
 
 There are two major clinical applications of gene editing: 
somatic cell engineering (SCE) and human germline modification 
(HGM). SCE typically entails editing copies of the affected gene 
in the differentiated cells of an adult or child.31 In theory, the 
patient’s germ cells are not affected during SCE, so the genetic 
changes are not passed down to the next generation.32 Somatic 
gene therapies are legal in the U.S., with many undergoing 
clinical evaluation.33 The first somatic gene therapy achieved 
market approval in the EU in 2012; however, commercial use has 
thus far been limited.34 
 In reproductive HGM35 the DNA of either an embryo or 
gametes is edited and the modified embryos or gametes are used 
                                                          
28 If the child is a female, she will pass the donor mtDNA to her progeny via 
her eggs. While a male child would carry the donor’s mtDNA, it would not 
pass the DNA down the germline because a father’s mtDNA is lost during 
fertilization. See Anne Claiborne, et al. Mitochondrial Replacement 
Techniques: Ethical, Social, and Policy Considerations, NAT’L ACADEMIES 
PRESS, 6-7 (2016), available at 
https://www.nap.edu/catalog/21871/mitochondrial-replacement-techniques-
ethical-social-and-policy-considerations. 
29 See Robert Kiltzman, et al., Controversies concerning mitochondrial 
replacement therapy, 103 FERTILITY & STERILITY 344-45 (Feb. 2015), available 
at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505924/pdf/nihms-
648296.pdf.  
30 Ewen Callaway, UK moves closer to allowing ‘three-parent’ babies, NATURE 
NEWS (Nov. 30, 2016), http://www.nature.com/news/uk-moves-closer-to-
allowing-three-parent-babies-1.21067.  
31 W.F. Anderson, Prospects for human gene therapy, 226 SCIENCE 402 (Oct. 25, 
1984), available at http://science.sciencemag.org/content/226/4673/401.  
32 Id. 
33 See Luigi Naldini, Gene therapy returns to centre stage, 526 NATURE 351 
(Oct. 15, 2015), available at 
http://www.nature.com/nature/journal/v526/n7573/full/nature15818.html.  
34 See Antonio Regalado, The World’s Most Expensive Medicine Is a Bust, MIT 
TECH. REV. (May 4, 2016), https://www.technologyreview.com/s/601165/the-
worlds-most-expensive-medicine-is-a-bust/.  
35 For the purposes of this paper HGM refers to the reproductive use of 
germline modification, not research on germline modifications that are done 
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for reproduction via IVF.36 The edit is made at the earliest 
possible stage of embryonic development; therefore, every cell of 
the resulting person carries the edited gene, including the germ 
cells.37 As a result, the altered gene will be propagated down the 
germline to the offspring.38  
 
b. Therapy and Enhancement using 
HGM 
 
 There are two general purposes for HGM treatment of 
embryos: (1) the correction of genetic diseases to produce a 
healthy child (therapy); and (2) the selection of specific desired 
traits in an otherwise healthy child (enhancement).39 The use of 
HGM for therapy would include the replacement of mutated 
genes with their functional, wild-type counterparts.40 This can be 
accomplished by deleting the former and inserting the latter, or 
by directly editing the mutated genes, resulting in a functional 
variant.41 Similarly, enhancement could be accomplished by 
adding new genes, deleting unwanted genes, and editing existing 
genes to create the desired phenotype.42 Both applications of 
HGM would create heritable changes to the patient’s genome. 
Accordingly, HGM has become extremely controversial and its 
                                                          
with no intention of implanting the embryo. Germline modification for 
research, while exceedingly important, is beyond the scope of this paper. 
36 See Tetsuya Ishii, Germline genome-editing research and its socioethical 
implications, 21 TRENDS IN MOLECULAR MED. 473-80 (Aug. 2015), available at 
http://www.cell.com/trends/molecular-medicine/pdf/S1471-4914(15)00107-
0.pdf. 
37 Id. 
38 See, e.g., Pradeep Reddy, Selective Elimination of Mitochondrial Mutation in 
the Germline by Genome Editing, 161 CELL 45 (Apr. 23, 2015), available at 
http://www.cell.com/cell/abstract/S0092-8674(15)00371-
2?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii
%2FS0092867415003712%3Fshowall%3Dtrue.  
39 The distinction between therapy and enhancement is not always crystal 
clear due to ambiguities in the meaning of “healthy” and “genetic diseases.” 
For the purposes of this paper, “therapy” refers to the treatment of serious 
genetic diseases that are caused by known genetic mutations and 
“enhancement” refers to the selection of traits for non-therapeutic purposes, 
including but not limited to selection of cosmetic features and the 
augmentation of intellectual capacity. 
40 See Naldini, supra note 33.  
41 See Jeffry D. Sander & J. Keith Joung, CRISPR-Cas systems for editing, 
regulating and targeting genomes, 32 NATURE BIOTECH. 347 (Jan. 31, 2014), 
available at http://www.nature.com/nbt/journal/v32/n4/full/nbt.2842.html.  
42 See id. 
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use is heavily regulated or banned in many countries around the 
world.43 
 
C. HGM Made Possible – CRISPR Genomic Editing 
Technology 
 
 CRISPR, (Clustered Regularly Interspaced Short 
Palindromic Repeats) is a gene-editing technique that has 
revolutionized the field of genetic engineering.44 The 
CRISPR/Cas9 system is composed of two parts: (1) the Cas9 
nuclease, which is the enzyme responsible for cutting DNA, 
allowing it to be edited; and (2) the guide RNA, which directs the 
Cas9 nuclease to the target site by binding to the corresponding 
sequence in the DNA.45 The CRISPR/Cas9 system is significantly 
more efficient than previous gene editing methods.46 Using 
automated RNA synthesis, new guide RNAs can be produced 
quickly and cheaply, making it possible to target and edit 
essentially any gene.47 The same nuclease can be used with two 
or more guide RNAs to edit multiple genes simultaneously.48 
Moreover, the Cas9 nuclease can be deactivated and combined 
with different enzymes, allowing for additional site-specific 
manipulation of DNA, including the conversion of a single 
nucleotide to a different nucleotide,49 nucleotide deletions50 and 
demethylation of target nucleotides.51 CRISPR’s modular 
                                                          
43 See Ishii, supra note 36. 
44 See id. 
45 See Martin Jinek, et al., A Programmable Dual-RNA-Guided DNA 
Endonuclease in Adaptive Bacterial Immunity, 337 SCIENCE 816 (Aug. 17 
2012), available at http://science.sciencemag.org/content/337/6096/816.full.  
46 See, e.g., Prashant Mali, et al., RNA-Guided Human Genome Engineering 
via Cas9, 339 SCIENCE 823, 825 (Feb. 15, 2013), available at 
http://science.sciencemag.org/content/339/6121/823.long.  
47 See Elizabeth Pennisi, The CRISPR Craze, 341 SCIENCE 833 (Aug. 23, 2013), 
available at http://science.sciencemag.org/content/341/6148/833.  
48 See, e.g., Le Cong, et al., Multiplex Genome Engineering Using CRISPR/Cas 
Systems, 339 SCIENCE 6121 (Feb. 15, 2013), available at 
http://science.sciencemag.org/content/339/6121/819.  
49 See, e.g., Alexis C. Komor, et al., Programmable editing of a target base in 
genomic DNA without double-stranded DNA cleavage, 533 NATURE 420, 420-
21 (May 19, 2016), available at 
http://www.nature.com/nature/journal/v533/n7603/full/nature17946.html.  
50 See, e.g., Keiji Nishida, et al., Targeted nucleotide editing using hybrid 
prokaryotic and vertebrate adaptive immune systems, 353 SCIENCE 1248 (Aug 
4, 2016), available at 
http://science.sciencemag.org/content/early/2016/08/03/science.aaf8729.full. 
51 See, e.g., Samrat Roy Choudury, et al., CRISPR-dCas9 mediated TET1 
targeting for selective DNA demethylation at BRCA1 promotor, 7 ONCOTARGET 
29 (Jun. 23, 2016), available at 
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versatility, unprecedented accuracy, ease of use, and low cost 
have opened the door to opportunities in genetic engineering that 
were considered fiction less than ten years ago. 
 In the three years since Jennifer Doudna and Emmanuel 
Charpentier’s landmark publication on CRISPR for gene editing, 
research in the field has expanded at a breakneck pace.52 The 
technique has led to rapid advances in the development of 
genetically-modified plants53 and customized animal models of 
diseases.54 In 2014, scientists used CRISPR to edit two genes in 
cynomolgus monkey embryos, leading to the birth of the first two 
genetically-modified monkeys.55 Earlier this year, the National 
Institutes of Health (NIH) approved a proposal for the clinical use 
of the technology to edit human T-cells as part of a cancer 
immunotherapy.56 Feng Zhang, MIT professor and CRISPR 
pioneer, told the MIT Technology Review that the actual gene 
editing of humans is only about “10 to 20 years away.”57 
 In fact, we may be much closer to HGM than anyone had 
originally anticipated. Earlier this year, researchers at the 
                                                          
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&pa
ge=article&op=view&path%5B%5D=10234.  
52 See Heidi Ledford, CRISPR: gene editing is just the beginning, 531 NATURE 
NEWS (Mar. 7, 2016), http://www.nature.com/news/crispr-gene-editing-is-just-
the-beginning-1.19510; Heidi Ledford, CRISPR, the disruptor, 522 NATURE 
NEWS (Jun. 3, 2015), http://www.nature.com/news/crispr-the-disruptor-
1.17673;  Addison V. Wright, et al., Biology and Applications of CRISPR 
Systems: Harnessing Nature’s Toolbox for Genome Engineering, 164 CELL 29 
(Jan., 2016), available at http://www.cell.com/cell/abstract/S0092-
8674(15)01699-2. 
53 See, e.g., Shigeo S. Sugano, et al., CRISPR/Cas9-mediated targeted 
mutagenesis in the liverwort Marchantia polymorpha L., 55 PLANT & CELL 
PHYSIOL. 475 (Jan. 18, 2014), available at 
http://pcp.oxfordjournals.org/content/55/3/475.long. 
54 See, e.g., Zhuchi Tu, et al. CRISPR/Cas9: a powerful genetic engineering tool 
for establishing large animal models of neurodegenerative diseases, 10 
MOLECULAR NEURODEGENERATION 35 (Aug. 4, 2015), available at 
https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s130
24-015-0031-x.  
55 See Yuyu Niu, et al., Generation of Gene-Modified Cynomolgus Monkey via 
Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos, 156 CELL 836 (Feb. 
13, 2014), available at http://www.cell.com/abstract/S0092-8674(14)00079-8; 
see also Helen Shen, First monkeys with customized mutations born, NATURE 
NEWS (Jan. 30, 2014), available at http://www.nature.com/news/first-monkeys-
with-customized-mutations-born-1.14611.  
56 Sara Reardon, First CRISPR clinical trial gets green light from US panel, 
NATURE (Jun. 22, 2016), available at http://www.nature.com/news/first-crispr-
clinical-trial-gets-green-light-from-us-panel-1.20137.  
57 See Antonio Regalado, Engineering the Perfect Baby, MIT TECH. REV. (Mar. 
5, 2015), https://www.technologyreview.com/s/535661/engineering-the-perfect-
baby/.  
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Oregon Health and Science University utilized CRISPR/Cas9 to 
achieve gene editing that resulted in viable human embryos.58 
The researchers were able to correct mutations in the MYBPC3 
gene that are responsible for hypertrophic cardiomyopathy, a 
condition that leads to sudden death in young athletes.59 Gene 
editing was successful in 42 out of 58 human embryos, with 41 of 
these embryos containing two healthy, wild-type copies of the 
MYBPC3 gene.60  Importantly, the techniques disclosed in this 
report appeared to surpass two significant hurdles to utilizing 
HGM by minimizing off-target gene edits and preventing 
mosaicism of the embryos.61 
 Prior to this report, CRISPR had already been used to edit 
human embryos. In 2015, the first report used CRISPR to alter 
the hemoglobin gene (HBB) in non-viable zygotes.62 The authors 
found that CRISRP/Cas9 system effectively cleaved the gene; 
however, the inefficiency of repair process and gene incorporation 
led to mosaicism of the embryo (embryos with cell-to-cell variation 
in genes). 63 The authors also detected off-target cleavage, 
indicating that the CRISPR/Cas9 system was not ready for 
clinical application.64 In the second paper written prior to the 
Oregon research, CRISPR was used on non-viable embryos to 
introduce a naturally-occurring gene involved in HIV 
resistance.65 Like the prior study, the authors found that the 
CRISPR system was not efficient enough to consider clinical 
applications.66 Although both of these studies used non-viable 
embryos that could not develop into a fetus, the news of 
engineered human embryos generated a significant amount of 
                                                          
58 Heidi Ledford, CRISPR fixes disease gene in viable human embryos, NATURE 
NEWS (Aug. 2, 2017), available at http://www.nature.com/news/crispr-fixes-
disease-gene-in-viable-human-embryos-1.22382.  
59 Hong Ma, et al., Correction of a pathogenic gene mutation in human embryos, 
548 NATURE 413-19 (Aug. 24, 2017), available at 
http://www.nature.com/nature/journal/v548/n7668/full/nature23305.html.  
60 Id. at 416. 
61 Id.  
62 Puping Liang, et al., CRISPR/Cas9-mediated gene editing in human 
tripronuclear zygotes, 6 PROTEIN & CELL 363 (Apr. 1, 2015), available at 
http://link.springer.com/article/10.1007/s13238-015-0153-5.  
63 Id. 
64 Id.  
65 Xiangjin Kang, et al., Introducing precise genetic modifications into human 
3PN embryos by CRISPR/Cas-mediated editing, 33 J. ASSIST. REPROD. 
GENET. 581-88 (Apr. 6, 2016), available at 
https://link.springer.com/article/10.1007%2Fs10815-016-0710-8.  
66 Id. 
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controversy.67 Scientists in the field have called for a voluntary 
worldwide moratorium on any application of CRISPR to the 
human germline.68 However, discussion is needed about the 
potential risks and benefits of the various clinical applications of 
CRISPR. 
 
III. CURRENT LAWS REGULATING HGM IN THE UNITED 
STATES 
 
A. FDA Jurisdiction over HGM 
 
 The FDA claims jurisdiction over HGM in the United 
States.69 The FDA has jurisdiction over “drugs,”70 medical 
“devices,”71 and “biological products.”72 In addition, it is the 
primary agency tasked with the review of applications of gene 
therapy.73 Thus, one likely source of the FDA’s jurisdiction over 
HGM is that modified gametes or embryos may constitute 
“biological products.”74 Alternatively, the FDA has the 
jurisdiction to regulate the use of “human cells or tissues that are 
intended for implantation . . . into a human,” which could include 
the modified embryo.75  Some have challenged the scope of the 
FDA’s authority to regulate procedures that utilize advanced 
                                                          
67 See, e.g., G. Burningham, We need to talk about human genetic engineering 
before it’s too late, NEWSWEEK (Apr. 30, 2016), 
http://www.newsweek.com/human-genome-editing-crispr-454315. 
68 Antionio Regalado, Industry Body Calls for Gene-Editing Moratorium, MIT 
TECH. REV. (Mar. 12, 2015), 
https://www.technologyreview.com/s/535846/industry-body-calls-for-gene-
editing-moratorium/.  
69 See Francis S. Collins, Statement on NIH funding of research using gene-
editing technologies in human embryos, U.S. DEP’T OF HEALTH & HUMAN 
SERVICES: NIH (April 28, 2015), https://www.nih.gov/about-nih/who-we-
are/nih-director/statements/statement-nih-funding-research-using-gene-
editing-technologies-human-embryos. 
70 21 U.S.C. § 321(g)(1). 
71 21 U.S.C. § 321(h). 
72 42 U.S.C. § 262(a). 
73 See Application of Current Statutory Authorities to Human Somatic Cell 
Therapy Products and Gene Therapy Products, 58 Fed. Reg. 53.248 (Oct. 14, 
1993); see also Emily Marden & Dorothy Nelkin, Displaced Agendas: Current 
Regulatory Strategies for Germline Gene Therapy, 45 MCGILL L.J. 461, 473-74 
(2000). 
74 See Elizabeth C. Price, Does the FDA have authority to regulate human 
cloning?, 11 HARV. J. LAW & TECH 619 (1998) (discussing the possible statutory 
basis for FDA authority over reproductive technologies, such as cloning). 
75 See 21 C.F.R. § 1271.3.  
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assisted reproduction technology (ART), such as cloning.76 While 
it is interesting to consider the full scope of the FDA’s authority 
to regulate HGM, such an analysis is beyond the scope of this 
paper. 
 As a result of the FDA’s authority over HGM, premarket 
approval and/or licensing would be required to market any 
germline correction therapy.77 As a necessary step in the process, 
an Investigational New Drug (IND) application must be filed with 
the FDA and the procedure must be subjected to rigorous clinical 
evaluation.78 It has been proposed that the FDA should apply an 
additional level of scrutiny to HGM, ensuring safety for both the 
children born from the process as well as any of those children’s 
offspring.79 However, clinical investigation into the safety of HGM 
is currently impossible in the U.S. under the existing legal 
framework.80 
 
B. The 2017 Rider 
 
 Human germline modification is currently banned in the 
United States, the result of a rider on the Consolidated 
Appropriations Act of 2016 (2016 Act).81 The rider first appeared 
in the House of Representatives’ draft of the Agriculture, Rural 
Development, FDA and Related Agencies Appropriations Act of 
2016.82 This draft was later incorporated into the 2016 Act, which 
was signed into law on December 18, 2015.83 Located in Division 
A, Title VII, section 749 of the 2016 Act, the rider reads as follows: 
 
                                                          
76 See Price, supra note 74; see also Marden, supra note 73 (briefly applying 
Price’s analytical framework to FDA jurisdiction over HGM).  
77 See 58 Fed. Reg. 53.248. 
78 See 21 C.F.R. § 312.20 (requiring an IND application for both new drugs 
under 21 U.S.C. 355(i) and biological products under 42 U.S.C. 262(a)(3)). 
79 Niklaus H. Evitt, et al., Human Germline CRIPSR-Cas Modification: 
Toward a Regulatory Framework, 15 AM. J. BIOETHICS 25 (Dec. 2, 2015), 
available at 
http://www.tandfonline.com/doi/full/10.1080/15265161.2015.1104160. 
80 See I. Glenn Cohen & Eli Y. Adashi, The FDA is prohibited from going 
germline, 353 SCIENCE 545 (Aug. 5, 2016), available at 
http://science.sciencemag.org/content/sci/353/6299/545.full.pdf. 
81  Consolidated Appropriations Act, 2016, Pub. L.  No. 114-13, 129 Stat. 2241, 
2282 (2015). 
82 Consolidated Appropriations Act of 2016, H.R. 2029, 114th Cong. (2015), 
available at https://www.congress.gov/ bill/114th-congress/house-bill/2029 
[hereinafter 2016 Act].  
83 Id. 
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 None of the funds made available by this Act may 
be used to notify a sponsor or otherwise acknowledge 
receipt of a submission for an exemption for 
investigational use of a drug or biological product 
under section 505(i) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355(i)) or section 351(a)(3) 
of the Public Health Service Act (42 U.S.C. 262(a)(3)) 
in research in which a human embryo is 
intentionally created or modified to include 
a heritable genetic modification. Any such 
submission shall be deemed to have not been 
received by the Secretary, and the exemption may 
not go into effect.84 
 
The rider remained in place as part of the Consolidated 
Appropriations Act of 2017, located in Division A, Title VII, § 736 
of the 2017 Act.85  This same rider is currently attached to the 
Senate draft of the Agriculture, Rural Development, FDA and 
Related Agencies Appropriations Act of 2018, which will likely 
become part of the Consolidated Appropriations Act of 2018.86 
Thus, there is a considerable chance that the effects of this rider 
will perpetuate for at least another year. 
 
C. Effect of the Rider 
 
 The rider effectively prevents the FDA from evaluating the 
safety and efficacy of any clinical therapy that requires a 
heritable genetic modification of a human embryo.87 As any 
treatment utilizing HGM necessarily results in a heritable 
genetic modification, these treatments are prohibited by the 
rider.88 The rider also has the effect of precluding the 
development of MRT, which can result in an embryo with 
                                                          
84 Consolidated Appropriations Act, 2016, Pub. L.  No. 114-13, § 749, 129 Stat. 
2241, 2283 (2015). 
85 Consolidated Appropriations Act, 2017, Pub. L. No. 115-31, § 736, 131 Stat. 
135 (2017) [hereinafter 2017 rider]. 
86 The rider is now included as § 734 of the bill. See Making appropriations for 
Agriculture, Rural Development, Food and Drug Administration, and Related 
Agencies programs for the fiscal year ending September 30, 2018, and for other 
purposes, S. 1603, 115th Cong. § 734 (as reported by S. Comm. on 
Appropriations, July 20, 2017), available at 
https://www.congress.gov/bill/115th-congress/senate-bill/1603/text.  
87 See Cohen & Adashi, supra note 80. 
88 See Sara Reardon, US Congress moves to block human-embryo editing, 
NATURE (Jun. 25, 2015), http://www.nature.com/news/us-congress-moves-to-
block-human-embryo-editing-1.17858. 
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alterations in its genome due to the incorporation of 
mitochondrial DNA from the donor.89 
 This blanket prohibition on HGM and MRT is achieved by 
blocking the FDA from reviewing or acknowledging the receipt of 
an IND Application.90 An IND or application for marketing 
approval can be obtained either by an application under section 
505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 
355(i)) or section 351(a)(3) of the Public Health Service Act (42 
U.S.C. § 262(a)(3)).91 By blocking both of these paths, the rider 
effectively precludes the FDA review required to initiate a clinical 
trial. 
 By precluding the FDA’s review of IND applications 
through either the “new drug” or “biological product” routes, the 
rider prevents scientists and clinicians from accurately assessing 
the safety and efficacy of HGM therapies.92 Although not 
technically a “ban” on HGM, the rider is sufficiently restrictive to 
preclude the clinical-stage research that is required to obtain 
either a new drug approval or a biological license.93 Without 
either of these, anyone attempting to practice HGM in the U.S. 
would be subject to severe civil penalties and/or criminal 
sanctions.94 Thus, the rider is a complete and effective deterrent. 
 
D. Additional Sources of Regulating in the 
United States 
 
 Although HGM is primarily regulated by the rider, there 
are several additional layers of regulation that are relevant to 
HGM. First, the NIH has some influence over the development of 
HGM through its ability to appropriate funding.95 As opposed to 
the FDA, the NIH does consider moral and ethical considerations 
                                                          
89 See Cohen & Adashi, supra note 80. 
90 Id. (citing National Academies of Sciences, Engineering, and Medicine, 
Mitochondrial Replacement Techniques: Ethical, Social, and Policy 
Considerations (National Academies, Washington, DC, 2016)). 
91 See 21 C.F.R. § 312.120 (2017). 
92 See Cohen & Adashi, supra note 80. 
93 See id. 
94 See, e.g., 42 U.S.C. § 262(f) (2017) (violations of 42 U.S.C. § 262(a)(3) (2017) 
are misdemeanors punishable by fines up to $500 and/or imprisonment up to 
one year); 42 U.S.C. § 262(d)(2) (2017) (civil penalties of up to $100,000 per day 
for biological products that are deemed by the Secretary to be a public health 
hazard); 21 U.S.C. § 333(a) & 333(e) (2017) (violations of 21 U.S.C. § 355(i) may 
be misdemeanors or felonies); 21 U.S.C. § 333(f) (2017) (civil penalties for 
violations pertaining to medical devices). 
95 Collins, supra note 69.  
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when allocating its funds.96 Currently, federal funds may not be 
used for research on HGM.97  The NIH guidelines indicate that 
the institute “will not at present entertain proposals for germline 
alteration,”98 precluding any NIH funding for this work.99 
 Second, the Dickey-Wicker Amendment (DWA) prohibits 
federal funding for most embryonic research.100 Specifically, the 
DWA prohibits the use of federal funds for: “(1) the creation of a 
human embryo or embryos for research purposes; or (2) research 
in which a human embryo or embryos are destroyed, discarded, 
or knowingly subjected to risk of injury or death.”101 As the 
clinical development of HGM would necessarily entail the 
creation of human embryos for research purposes, the DWA 
would prevent federal funds from being used to develop this 
technology.102 However, these policies have no effect on the 
legality of privately-funded research.103 
 
IV. INTERNATIONAL LAWS REGULATING HGM 
 
 The current status of international HGM regulation is a 
mosaic of laws, guidelines, and recommendations.104 A study from 
2014 found that 29 countries had a statutory ban on germline 
editing. 105 However, in some of those countries with a statutory 
                                                          
96 See, e.g., Guiding Principles for Ethical Research, NAT’L INSTITUTES OF 
HEALTH, GUIDING PRINCIPLES FOR ETHICAL RESEARCH, 
https://www.nih.gov/health-information/nih-clinical-research-trials-
you/guiding-principles-ethical-research.  
97 Collins, supra note 69. 
98 Id. at 51. 
99 The Collins statement does not discuss the modification of human gametes 
for research purposes. It is possible that such research may still be eligible for 
NIH funding.  
100 See Erik Parens & Lori P. Knowles, Reprogenetics and Public Policy: 
Reflections and Recommendations, HASTINGS CTR. REP. S11, S13 (2003), 
available at http://www.thehastingscenter.org/wp-
content/uploads/reprogenetics_and_public_policy.pdf.  
101 Consolidated Appropriations Act, 2017, Pub. L. No. 115-31, § 508, 131 Stat. 
135 (2017). 
102 Collins, supra note 69. 
103 See Parens & Knowles, supra note 100. 
104 See Heidi Ledford, Where in the World Could the First CRISPR Baby be 
Born?, 526 NATURE 310, 311 (Oct. 15, 2015), available at 
http://www.nature.com/news/where-in-the-world-could-the-first-crispr-baby-
be-born-1.18542; see also Sara Reardon, Global summit reveals divergent views 
on human gene editing, 528 NATURE 173 (Dec. 8, 2015), available at 
http://www.nature.com/news/global-summit-reveals-divergent-views-on-
human-gene-editing-1.18971.  
105 Motoko Araki & Tetsuya Ishii, International regulatory landscape and 
integration of corrective genome editing into in vitro fertilization, 12 REPROD. 
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ban, such as in Belgium, Bulgaria, Canada, and Sweden, there 
may be ambiguity as to what is proscribed by these laws.106 For 
example, it is ambiguous whether a germline correction that 
resulted in a wild-type gene would actually be banned under the 
laws of these countries.107 Moreover, the guidelines that ban 
HGM in China, India, Ireland, and Japan may not be strictly 
enforced.108 Of the legality of the procedure in ten other countries, 
nine were also ambiguous.109 In the absence of a clear worldwide 
consensus, this fluid patchwork of international regulation will 
probably leave sufficient room for HGM research to continue 
somewhere in the world.110 Two of the countries that may be most 
likely to influence HGM regulation in the US are the United 
Kingdom and China.  
 
A. The United Kingdom 
 
 The U.K. has one of the most comprehensive regulatory 
systems in the world for assessing the scientific and medical 
merits of new fertilization technology. In the United Kingdom, 
IVF and other more advanced ART procedures are under the 
regulation of the Human Fertilization and Embryology Authority 
(HFEA).111 The HFEA is an independent regulatory body that 
oversees research and fertility treatments that utilize gametes 
and embryos.112 The HFEA was created in 1990 with the passage 
of the Human Fertalisation and Embryology (HFE) Act of 1990, 
which was recently amended in 2008.113 
 The U.K. is the most progressive country in the world with 
respect to the use of MRT; in fact, clinics in the U.K. may begin 
performing MRT as early as this year. The HFEA recently 
announced that authorized clinics may apply to the HFEA for 
                                                          
BIOL. ENDOCRINOL. 108, (Nov. 24, 2014), available at 
https://rbej.biomedcentral.com/articles/10.1186/1477-7827-12-108.  
106 See Ishii, supra note 36.  
107 Id. 
108 Id. 
109 Id. 
110 Lauren F. Friedman, These are the countries where it’s ‘legal’ to edit human 
embryos (hint: the US is one), BUSINESS INSIDER (Apr. 23, 2015, 2:15 PM), 
http://www.businessinsider.com/china-edited-human-genome-laws-2015-4. 
111 See HUMAN FERTILISATION & EMBRYOLOGY AUTHORITY; 
http://www.hfea.gov.uk (last visited Dec. 21, 2017). 
112 See id.  
113 See IVF the Law, HUMAN FERTILISATION & EMBRYOLOGY AUTHORITY (July 
25, 2013), 
http://hfeaarchive.uksouth.cloudapp.azure.com/www.hfea.gov.uk/134.html.  
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license to treat patients using MRT.114 Parliament passed 
regulations permitting the use of MRT in February 2015 and the 
regulatory framework was put into place in October of 2016.115 
However, the HFEA delayed their announcement until after they 
received the official recommendations of the appointed expert 
panel. The scientific panel recommended the use of MRT “as a 
risk reduction treatment for carefully selected patients.”116 The 
panel also recommended that the procedures be coupled with 
prenatal testing and restricted to patients that do not have viable 
alternatives, such as PGD.117  
 Obtaining authorization to treat a patient with MRT 
requires a two-step process. First, a clinic must be reviewed by 
the HFEA’s License Committee, who assess the clinic’s skill, 
experience, and facilities.118 Next, the clinics must apply to the 
Statutory Approvals Committee (SAC) for authorization to treat 
any individual patient.119 After approval by both the HFEA and 
the SAC, the clinics may perform MRT on the authorized patient 
using either Maternal Spindle Transfer or Protonuclear Transfer 
techniques.120 
 The regulation of HGM with CRISPR/Cas9 is far more 
stringent than those governing MRT. As of early 2016, only one 
molecular biologist, Kathy Niakan, has been granted permission 
to perform gene editing in human embryos.121 However, the 
embryo must be destroyed within 14 days and no embryo may be 
implanted into a woman.122 Moreover, no research can be 
undertaken without explicit approval from the HFEA ethics 
                                                          
114 See HFEA permits cautious use of mitochondrial donation in treatment, 
following advice from scientific experts, HUMAN FERTILISATION & 
EMBRYOLOGY AUTHORITY (Dec. 15, 2016), 
http://hfeaarchive.uksouth.cloudapp.azure.com/www.hfea.gov.uk/10563.html.  
115 Id. 
116 See UK’s independent expert panel recommends “cautious adoption” of 
mitochondrial donation in treatment, HUMAN FERTILISATION & EMBRYOLOGY 
AUTHORITY (Dec. 15, 2016), 
http://hfeaarchive.uksouth.cloudapp.azure.com/www.hfea.gov.uk/10559.html.  
117 Id. 
118 Id. 
119 Id.  
120 Id. 
121 See HFEA approval for new “gene editing” techniques, FRANCIS CRICK 
INSTITUTE (Feb. 1, 2016), https://www.crick.ac.uk/news/science-
news/2016/02/01/hfea-decision/.  
122 See Fiona MacDonald, 10 things you need to know about the UK allowing 
genetic modification of human embryos, SCIENCE ALERT (Feb. 2, 2016), 
http://www.sciencealert.com/10-things-you-need-to-know-about-the-uk-s-
decision-to-allow-genetic-modification-of-human-embryos.  
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committee.123 Although the use of HGM for reproduction is 
prohibited in the U.K., their recent approval of MRT indicates 
that the U.K. may be among the first nations to approve of 
therapeutic applications of HGM. 
 
B. China 
 
 China was the first country to report the editing of the 
human germline.124 Accordingly, the regulation of HGM in China 
has become a hot topic of debate in the past two years.125 Many in 
the West have accused the Chinese of being lackadaisical with 
enforcement of regulations against HGM.126 However, others 
argue that China’s ethical stance on the issue is not substantially 
different than the United States or Europe.127 For example, 
Chinese guidelines on HGM stipulate that “gene manipulation on 
human game[te], zygote and embryo for the purpose of 
reproduction is banned.”128 
 In China, HGM is regulated by a detailed regulatory 
framework.129 Regulations promulgated by China’s Ministry of 
Health130 include the Ethical Principles for ART and the Human 
Sperm Bank of 2003, the Ethical Principles on ART of 2001, and 
The Interim procedures for Human Genetic Resources 
Management of 1998.131 The State Council has published a 
preliminary draft of The Regulation of the Human Genetic 
Resources, which will eventually replace the 1998 interim 
                                                          
123 Id. 
124 See Liang, et al., supra note 62. 
125 See, e.g., Sarah Knapton, China shocks world by genetically engineering 
human embryos, THE TELEGRAPH (Apr. 23, 2015, 2:36 PM), 
http://www.telegraph.co.uk/news/science/11558305/China-shocks-world-by-
genetically-engineering-human-embryos.html; G. Owen Schaefer, China may 
be the future of genetic enhancement, BBC FUTURE (Aug. 8, 2016), 
http://www.bbc.com/future/story/20160804-china-may-be-the-future-of-
genetic-enhancement.  
126 See, e.g., Rebecca Taylor, Mad Scientists in China Attempt to Create 
Genetically-Modified Babies, It Didn’t Go Well, LIFENEWS.COM (Apr. 24, 2015), 
http://www.lifenews.com/2015/04/24/mad-scientists-in-china-attempt-to-
create-genetically-modified-babies-it-didnt-go-well/.  
127 See Xiaomei Zhai, et al., No ethical divide between china and the West in 
human embryo research, 16 DEVELOPING WORLD BIOETHICS 116 (Jan. 21, 
2016), available at http://onlinelibrary.wiley.com/doi/10.1111/dewb.12108/full.  
128 Id. at 118. 
129 See id.  
130 The MoH is now known as the National Health and Family Planning 
Commission. Id. 
131 See Zhai, supra note 126, at 118 (and references therein).  
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procedures.132 The net effect of these regulations is a system very 
similar to those of many western countries, requiring informed 
consent by participants and providing an absolute ban on the use 
of HGM in reproduction.133 Nevertheless, the current law in 
China amounts to non-binding guidelines and as a result, 
development of HGM might continue in the future.134 
 
V. Statement of the Issue 
 
 The United States should amend the rider on the 
Consolidated Appropriations Act of 2019 (2019 Act) to create an 
exception to its current prohibition of HGM that would allow the 
FDA to receive and review applications pertaining to the use of 
HGM for the treatment of heritable monogenic diseases where the 
edit would result in a wild-type gene. Such an exception would 
provide a number of benefits, while minimizing the current safety 
and ethical concerns surrounding HGM. Moreover, this would set 
a precedent that would have a positive impact on the 
international regulation of HGM, leading other countries to 
seriously consider legalization and regulation. Although a similar 
exception should also be made to facilitate the practice of MRT, a 
full discussion of the policy implications leading to this suggestion 
are beyond the scope of this paper. 
 
VI. ANALYSIS  
 
 Unless and until the United States is prepared to adopt a 
formal legislative scheme to regulate HGM, there are three main 
legislative options available: (1) completely remove the rider from 
the 2019 Act; (2) leave the intact rider in place for the foreseeable 
future; or (3) keep the rider in place and adopt a specific exception 
or exceptions, such as those that would allow the FDA to receive 
and review IND applications for the use of HGM to treat specific 
monogenic diseases. The Author encourages the pursuit of the 
third option for reasons that are discussed in the balance of this 
article. 
 
A. Rationale Behind the Rider 
 
                                                          
132 Id. 
133 Id. 
134 See Ishii, supra note 36. 
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 The House of Representatives Committee Report, which 
accompanied the 2016 Act, outlined the Congressional concerns 
that led to the rider’s adoption:  
 
 The Committee understands the potential 
benefits to society in the genetic modification of 
living organisms. However, researchers do not yet 
fully understand all the possible side effects of 
editing the genes of a human embryo. Editing of the 
human germ line may involve serious and 
unquantifiable safety and ethical issues. Federal 
and non-Federal organizations such as the National 
Academy of Sciences and National Academy of 
Medicine will soon engage in more extensive 
scientific analysis of the potential risks of genome 
editing and a broader public discussion of the 
societal and ethical implications of this technique. In 
accordance with the current policy at the National 
Institutes of Health, the Committee includes bill 
language that places a prohibition on the FDA’s use 
of funds involving the genetic modification of a 
human embryo. The Committee continues to support 
a wide range of innovations in biomedical research, 
but will do so in a fashion that reflects well-
established scientific and ethical principles.135 
 
From the text above, it is evident that the two predominant 
Congressional concerns that led to the rider were those of safety 
and ethics. Moreover, this passage indicates that future policies 
on the subject must reflect “well-established scientific and ethical 
principles.”136 
 Statements made during the hearing on “The Science and 
Ethics of Genetically Engineered Human DNA” may shed some 
light on these Congressional concerns.137 In the Statement of 
Lamar Smith (R-TX), several points were raised.138 First, there is 
                                                          
135 See Report of the House Committee on Appropriations, Together with 
minority views (to accompany H.R. 3049) (2015), 
https://www.congress.gov/114/crpt/ hrpt205/CRPT-114hrpt205.pdf. 
136 Id. 
137 The Science and Ethics of Genetically Engineered Human DNA: Hearing 
Before the H. Comm. on Science, Space, and Technology, 114 Cong. 8-9 (2015) 
(statement of Lamar Smith, Chairman of the Subcomm. on Research and 
Technology), available at http://bit.ly/HouseSciCtte [hereinafter Lamar 
Smith].  
138 Id. 
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a need “to prevent dangerous abuses and unintended 
consequences” that might result from the inappropriate use of 
this technology.139 Second, the U.S. should take the lead in the 
scientific development and ethical application of genetic 
engineering.140 Finally, our current technological understanding 
of the CRISPR/Cas9 system needs to be refined so that patients 
can be assured safe and ethical treatment.141  
 Some commenters contend that the major—if not only—
Congressional concern is that of ethics, not safety.142 For one, the 
FDA already thoroughly investigates the safety of any procedure 
during the IND application and subsequent clinical trials.143 
Before any clinical trial commences, an applicant must prove that 
the proposed drug is likely to be safe and effective by providing 
data from extensive preclinical testing.144 During clinical 
evaluation, the FDA requires standardized protocols,145 detailed 
records,146 safety reports,147 and oversight by the Institutional 
Review Board.148 Furthermore, if at any point during clinical 
evaluation, the process does not appear safe, they may stop the 
trial by placing it on “clinical hold.”149 Although inheritable 
germline alterations may be unique insofar as they effect the 
offspring of those who have undergone the therapy,150 the FDA 
may already be well-suited to evaluate applications for 
                                                          
139 Id. at 8. 
140 Id. (noting that “the United States can and should provide scientific and 
moral leadership” in the field of HGM and “must take the lead in reviewing 
new and innovative areas of science, such as genetically engineered DNA.”) 
141 Id. (emphasizing the “need to better understand the technology and 
procedures being used so that we can ensure patients are treated in the safest 
and most ethical manner possible”). 
142 See, e.g., Regalado, supra note 57 (quoting Professor Hank Greely as saying, 
“I would not want to use safety as an excuse for a non-safety-based ban,” when 
referring to the rider).  
143 See generally U.S. DEPT. OF HEALTH & HUMAN SERV., SAFETY REPORTING 
REQUIREMENTS FOR INDS AND BA/BE STUDIES: GUIDANCE FOR INDUSTRY AND 
INVESTIGATORS (2012), available at 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM227351.pdf.  
144 Food & Drugs Act, 21 U.S.C. § 355(i)(1)(A) (2015) (requiring “the submission 
to the Secretary before any clinical testing of a new drug is undertaken, of 
reports . . .  preclinical tests (including tests on animals) of such drug adequate 
to justify the proposed clinical testing”). 
145 21 C.F.R. § 312.23(a)(6) (2017). 
146 21 C.F.R. §§ 312.57, 312.62, 312.64. 
147 21 C.F.R. § 312.32. 
148 21 C.F.R. § 312.66. 
149 21 U.S.C. § 355(i)(3)(B)(i). 
150 Edward Lanphier, et al., Don’t edit the human germ line, 519 NATURE 410, 
410-11 (Mar. 26, 2015), available at http://www.nature.com/news/don-t-edit-
the-human-germ-line-1.17111. 
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therapeutic HGM by applying enhanced scrutiny to its existing 
IND procedure.151 
 While evaluation of safety is squarely within the FDA’s 
jurisdiction, ethical or moral review is not.152  Congress has never 
before used the FDA to enforce a prohibition on germline 
modification.153 By precluding FDA review concerning the safety 
and efficacy of any potential HGM applications, lawmakers have 
demonstrated that they consider the ethical implications of HGM 
to be the overriding concern. Interestingly, the rider was passed 
only a few weeks after a summit, where the committee 
highlighted the need to further evaluate the safety and ethics of 
germline modification, discussed in greater detail below.154 It is 
possible that the intention of the rider is to ensure a sound ethical 
evaluation of HGM before proceeding to the assessment of its 
safety.  
 These considerations of safety and ethics, as they apply to 
each potential option, are considered below, with an emphasis on 
relevant ethical issues. The potential effect of each policy on the 
leadership of the U.S. in the field of HGM is also discussed.  
 
B. Evaluation of Potential Policy Options 
 
1. Refusal to Renew the Rider 
 
 Congress could refuse to renew the rider for the 2019 Act. 
This would lift the ban on FDA receipt and review of any IND 
applications for the use of HGM. Importantly, this would 
potentially allow the clinical evaluation of HGM for both 
therapeutic uses and non-therapeutic enhancement procedures. 
Given the infancy of the technology, as well as the current 
widespread disapproval of non-therapeutic applications of HGM, 
failure to renew the rider is highly unlikely. Moreover, it may be 
an ethically undesirable outcome that could lead to severe 
unintended consequences for the industry.  
 
                                                          
151 Evitt, supra note 79.  
152 See 21 U.S.C. § 301 et seq.; Fed. Reg. 53.248, supra note 73; PRESIDENT’S 
COUNCIL ON BIOETHICS (U.S.), REPRODUCTION & RESPONSIBILITY: REPORT ON 
THE REGULATION OF NEW BIOTECHNOLOGIES xii (2004), available at 
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a. Plausibility 
 
 Complete removal of the rider may not be popular given the 
current status of public opinion concerning the propriety of 
HGM.155 A recent Pew Research Center poll indicated that a 
significantly portion of the U.S. public is worried about the 
prospect of HGM (68%), and a much smaller population is 
enthusiastic about the subject (49%).156 As the public is 
significantly more adverse to the idea of genetic enhancements 
than it is germline therapy, any policy that fails to draw a 
distinction between therapeutic and non-therapeutic 
enhancement is not likely to be received with public approval.157 
Lack of public support among Congressional constituencies may 
translate to less Congressional votes against renewing the rider. 
 Any attempt to repeal the rider in its entirety is 
particularly unlikely to succeed because it would theoretically 
enable FDA review of HGM for non-therapeutic enhancements. 
The most zealous critiques of HGM pertain to its use in non-
therapeutic enhancement and the possibility of eugenic 
applications.158 Even among commenters who acknowledge the 
potential utility of corrective germline therapy, many caution 
against therapeutic use because of fears that it may lead to a 
slippery slope resulting in non-therapeutic or eugenic 
applications.159 Any action that opens up the possibility for 
genetic enhancement is not likely to be well received. 
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156 Cary Funk, et al., U.S. Public Wary of Biomedical Technologies to ‘Enhance’ 
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RES. CTR. REP. (Jul. 26, 2016), available at 
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the risk of serious diseases). 
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2016), http://www.nationalgeographic.com/magazine/2016/08/human-gene-
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Striking a Balance: Policy Considerations for Human Germline Modification 85 
b. Safety and Ethical Implications 
 
 Nor is it necessarily desirable to permit the application of 
HGM to non-therapeutic enhancement, as such application raises 
significant ethical concerns. While supporters of HGM for 
enhancement offer a variety of arguments in favor of the 
practice,160 such practices raise deep-rooted concerns about the 
close relationship between genetic enhancement and eugenics.161 
The eugenics movement has been roundly criticized for promoting 
a bigoted concept of genetic superiority based on race, class, 
religious, and sexual prejudices.162 The American eugenic 
movement led to the forced sterilization of over 64,000 people163 
and may have contributed to the use of African-American men for 
the Tuskegee study of untreated syphilis.164 Moreover, the 
eugenic practices of Nazi Germany were modeled at least in part 
by eugenics laws in U.S. states, particularly those in California.165 
Given the potential social harm that could result from the eugenic 
applications of HGM, use of this technology requires exceptionally 
strong validation, which is lacking in the case of non-therapeutic 
uses. 
 Some commentators have argued that the “new eugenics” 
of the 20th Century is different than the “old eugenics” of historic 
infamy and they highlight several distinctions between the 
                                                          
160 See, e.g., NICHOLAS AGAR, LIBERAL EUGENICS: IN DEFENSE OF HUMAN 
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Eugenics Movement, NATURE EDUC. (Sept. 18, 2014), 
http://www.nature.com/scitable/forums/genetics-generation/america-s-hidden-
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164 See Allan Brandt, Racism and Research: The Case of the Tuskegee Syphilis 
Study, in SICKNESS AND HEALTH IN AMERICA, 331, 331-43 (Judith Leavitt & 
Ronald Numbers eds., 2nd ed. 1985). 
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two.166 First, many of the tragedies of the old eugenic movement, 
such as forced sterilizations of convicted criminals and people 
with mental disabilities, were the result of government control.167 
Enhancement applications of HGM would be guided by the 
choices of individual parents, not government mandate, thereby 
reducing the risk that such events would be repeated.168 Second, 
society now has a more advanced understanding of the basic 
biology of heredity than it did in the early 19th century.169  
 Opponents of this viewpoint argue this “new eugenics” of 
genetic choice would lead to the same results as the “old 
eugenics.”170 To begin with, there are several forces that may 
undermine a parent’s autonomy in deciding to enhance their 
children.171 In some situations, there may be community pressure 
on a parent to obtain a specific enhancement for their child.172 
Thus, the individual autonomy used to validate the “new 
eugenics” may not be as clear of a distinction as its proponents 
suggest.   
 There are also significant safety concerns that weigh 
against the use of HGM for enhancement. Most importantly, the 
traits that are most desirable to enhance are too complex to 
achieve safe editing in human embryos, even if the technology 
evolves to the point that prevention of monogenic diseases 
becomes facile and safe. Traits such as height or intelligence are 
controlled by potentially hundreds of genes.173 With every 
additional edit, the chances of an off-target mutation grow 
exponentially, increasing the probability of a serious adverse 
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LINACRE Q. 239, 240 (Aug. 2014), available at 
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Human Enhancement, 41 HASTINGS CTR. REP. 32 (Jan. 2011), available at 
http://onlinelibrary.wiley.com/doi/10.1002/j.1552-
146X.2011.tb00098.x/abstract?wol1URL=/doi/10.1002/j.1552-
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171 Id. at 37-38.  
172 Id. at 38-39. 
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event. With the technology still in its infancy, attempting such 
experiments would constitute an unacceptable safety risk with a 
high probability of treatment leading to an adverse event.  
 
2. Leaving the Rider Intact for Future Years 
 
 The second option is to leave the language of the current 
rider intact for the 2019 Act. Absent significant lobbying effort on 
behalf of the biotech industry, this may be the most likely outcome 
for the foreseeable future. Similar riders have carried substantial 
legislative inertia in the past, eventually becoming the “new 
normal.” However, significant harm may result from such a 
course because it may prevent the development of life-saving 
therapies.  
 
a. Plausibility 
 
 Riders pertaining to reproductive choice have exhibited 
striking longevity.174 For example, the DWA has been in effect for 
twenty years.175 The DWA was originally attached to an 
appropriations bill for the Department of Labor, Health and 
Human Services and later became part of the Continuing 
Resolution for Fiscal Year 1996.176 In addition, the Hyde 
Amendment, which restricts the use of federal funds to pay for 
abortion services, has been law for over four decades.177 The Hyde 
Amendment was originally attached to the annual appropriations 
bill in 1976.178 Both of these examples illustrate the fact that 
riders governing reproductive health have considerable long-term 
staying power. If a concerted effort is not made to change the 
                                                          
174 See Cohen & Adashi, supra note 80. 
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current rider, the blanket prohibition on HGM could continue for 
decades to come. 
 
b. Safety and Ethical Implications 
 
 This path of least resistance is not without its own risks. 
The longer the rider remains in place, the more difficult it may be 
to repeal, as it becomes the “new normal.”179 If this broad 
prohibition remains in place for too long, it may have the 
unintended effects of (1) chilling important therapeutic research; 
(2) causing the U.S. to forfeit its place as the world leader in the 
scientific and ethical debate; and (3) preventing potential parents 
from obtaining access to HGM for the treatment of debilitating 
genetic diseases.  
 First, the rider may have the effect of chilling necessary 
research and development on therapeutic gene editing in the U.S. 
Long-term riders have already produced unfortunate 
consequences for the scientific community.180 For example, the 
DWA was present on the appropriations bill in 2009, which 
President Obama signed just two days after lifting President 
Bush’s executive order banning federal funding for stem cell 
research.181 In 2010, the DWA was used to obtain a federal 
injunction against federally-funded stem cell research that had 
been approved by President Obama’s executive order.182 The 
injunction was overturned the next year by the Court of Appeals 
for the District of Columbia.183 Nevertheless, the uncertainty 
caused by the temporary injunction disrupted the field of stem 
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cell research, leading to a chilling effect on research and the loss 
of valuable resources.184 To avoid similar uncertainty in the policy 
around HGM, it would be prudent to amend the current rider 
before it leads to a similar result.  
 Second, the rider’s continued presence may prevent the 
U.S. from “provid[ing] scientific and moral leadership” in the 
field, thereby impeding another Congressional objective.185 Some 
have already argued that the current regulatory framework puts 
the U.S. at risk of falling behind in the development of gene 
therapy.186 As of April 2016, experiments utilizing CRISPR/Cas9 
on human embryos had either been approved or already 
performed in China, Sweden, and the United Kingdom.187 More 
experiments are likely to be approved in the near future, causing 
the U.S. to lag behind in the research and development of HGM. 
Falling behind on the scientific development of HGM in the long 
term may negatively affect our legitimacy in the international 
community, undermining our leadership role in important ethical 
and scientific discussions.  
 Third and most importantly, failure to amend the rider 
may prevent parents from having access to potentially life-saving 
treatment, creating unnecessary suffering and increasing the 
financial burden on the healthcare system.  The WHO indicates 
that “[t]he global prevalence of all single gene diseases at birth is 
approximately 10/1,000.”188 It is estimated that monogenic 
diseases affect up to 13 million people in the U.S., causing nearly 
one-fifth of infant mortality.189 Many of the thousands of 
monogenic diseases lead to severe physiological impairment or 
early death.190 Prevention of these diseases using HGM could 
prevent suffering for those afflicted as well as their family 
members. 
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 Some proponents of the ban contend that the development 
HGM is not necessary because alternative means would be 
effective in a majority of cases.191 For example Eric Lander notes 
that “it would be easier and safer simply to use PGD . . . in the 
typical cases of a parent heterozygous for a dominant disease or 
two parents who are carriers for a recessive disease.”192 Lander 
concludes that situations that would necessitate HGM are 
“vanishingly rare for most monogenic diseases.”193  
 Nevertheless, there are clearly situations in which HGM 
might be required and in those cases, the real benefit to the 
parents and children outweighs the speculative harm that drives 
much of the opposition to HGM. For example, PGD would not be 
sufficient when one parent is homozygous for an autosomal 
dominant disease or both parents have a homozygous autosomal-
recessive disease.194 Incidences of homozygosity have already 
been documented in several deadly monogenic diseases, including 
cystic fibrosis195 and Huntington’s disease.196 For these people, 
the choices are clear: obtaining treatment using HGM, rearing a 
sick child, or abstaining from procreation. Although these 
situations may be rare, those inflicted are still human. Preventing 
these people from receiving treatment should not be morally 
justified by references to the speculative harm that may be 
brought about by potential cosmetic applications of HGM.  
 
3. Amend the Rider to Include a Specific 
Exception 
 
 The third option available to Congress is to amend the 
rider, providing for specific exceptions for particular applications 
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of HGM. For example, it would be sensible to allow the use of 
HGM in the treatment of selected, well-studied monogenic 
diseases. A specific exception for the use of HGM in monogenic 
diseases would provide for the most ethically sound use of the 
technology. Such an exception could help save human lives, 
reduce the costs associated with genetic diseases, and protect the 
reproductive freedom of individuals. Furthermore, these 
exceptions would allow the scientific freedom that is necessary for 
the U.S. to remain at the technical and ethical forefront of this 
emerging technology. The author proposes one such exception. 
 The proposed amended rider reads as follows, where the 
bold text indicates the amendment:   
 
 None of the funds made available by this Act may 
be used to notify a sponsor or otherwise acknowledge 
receipt of a submission for an exemption for 
investigational use of a drug or biological product . . 
. in which a human embryo is intentionally created 
or modified to include a heritable 
genetic modification, with the exception of a 
submission pertaining to the treatment of 
embryos where there is a substantial risk that 
the child will be born with a severe or life-
threatening genetic disease,  where the 
disease has a well-established and specific 
genetic cause, where the modification results 
in wild-type gene, and where the patients 
could not obtain equally effective treatment 
using other means. Any such submission shall be 
deemed to have not been received by the Secretary, 
and the exemption may not go into effect.197 
 
a. Plausibility 
 
 Amending the rider would not be unprecedented; riders 
have been known to evolve over time. For example, the Hyde 
Amendment initially provided a full ban on the use of federal 
funds for abortion services.198 Since then, the Hyde Amendment 
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has been changed several times.199 In 1981, the amendment was 
altered to include an exception “where the life of the mother would 
be endangered if the fetus was carried to term.”200  It was changed 
again in 1993, expanding federal funding to abortions related to 
incidents of rape and incest.201 The first explicit call to repeal the 
amendment was not until 2016.202  
 The proposed exception would reflect the differences in 
public opinion between the use of HGM for therapy and its use for 
enhancement. Polls indicate that people in the United States are 
significantly less concerned about the use of genetic engineering 
to treat disease than they are about its use for enhancement or 
trait selection.203 In fact, 59% of parents with a child under the 
age of 18 said that they would want gene editing to reduce their 
baby’s risk of disease, while only 39% of these parents indicated 
that they would not.204 As people learn more about the subject, it 
is likely that their attitudes will shift in favor of therapeutic 
HGM.205  
 
b. The Proposed Exception is in Line with 
Expert Consensus 
 
 The proposed exception is generally in line with the 
recommendations from the National Academy of Sciences and the 
National Academy of Medicine, which were released earlier this 
year in the Human Genome Editing Report (the Report).206 The 
Report was authored following the conclusion of the 2015 
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International Summit on Human Gene Editing.207 Its authors 
include experts in science, medicine, and public policy from 
around the world.208 The Report was compiled after an extensive 
review of the literature, as well as discussions with clinicians, 
researchers, policymakers, and patient advocates, among 
others.209 Thus, the Report represents over a year of concerted 
effort by a collection of some of the most qualified experts in the 
world and their recommendations should be afforded due 
consideration. 
 The two major recommendations with respect to HGM 
were (1) to “[p]ermit clinical research trials only for compelling 
purposes of treating or preventing serious disease or disabilities, 
and only if there is a stringent oversight system able to limit uses 
to specified criteria”; and (2) that “[o]ngoing reassessment and 
public participation should precede any heritable germline 
editing.”210 The committee defined a set of criteria for the clinical 
use of HGM in treating disease that closely mirrors the proposed 
amendment.211 With respect to genetic enhancement, the 
Academies suggested “not [to] proceed at this time with human 
genome editing for purposes other than treatment or prevention 
of disease and disability.”212 Adoption of the proposed amendment 
— or something of similar scope — would ensure that the 
committee’s recommendations are respected, and HGM would not 
be applied recklessly.  
 
c. The IOM Report Further Bolsters the 
Case for an HGM Exception 
 
 Congress may already have to amend the FDA rider to 
accommodate recommendations by the Institute of Medicine 
(IOM), which suggested that the U.S. move forward with limited 
clinical trials for MRT. As the rider has been interpreted to 
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preclude any clinical evaluation of MRT, Congress may have to 
amend the rider if they are to heed the recommendations of the 
IOM report.213 
 In 2016, the IOM provided a report at the request of the 
FDA and the National Academies proposing a path forward for 
the clinical application of MRT. 214 Acknowledging that the FDA’s 
purview extends only to safety and efficacy, the IOM committee 
specifically reviewed the “social, ethical and policy” 
considerations of MRT.215 They concluded that most of the 
concerns about germline modification (1) could be “avoided 
through limitations on the use of MRT” or (2) “are blunted by 
meaningful differences between the heritable genetic 
modification of nDNA and that introduced by MRT.”216 
 First, the report suggested that only limited applications of 
MRT should be evaluated, especially at the early stages of 
development.217  In addition to other restrictions,218 the IOM 
recommended that the clinical evaluation of MRT should proceed 
for clinical trials that involved “transferring only male embryos 
for gestation to avoid introducing heritable genetic 
modification[.]”219 This is because the mtDNA from the father is 
not passed on during procreation,220 which may be caused by 
degradation of the mtDNA during fertilization of an oocyte.221 
Only the mother’s mtDNA are passed down to the children.222 
Because the male children could not pass on the donor’s mtDNA, 
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the use of MRT to treat male children would not result in a 
“heritable genetic mutation.”223 
 Second, the committee noted that there were “significant 
and important distinctions between [the] modification of mtDNA 
and nDNA[,]” which affect the ethical, social, and policy 
considerations for MRT.224 For example, although “mtDNA plays 
a central role in genetic ancestry,” the traits encoded in nDNA 
“are those that in the public understanding” are more important 
for genetic relatedness . . . and disease.225 Moreover, while 
mtDNA may be used for “energetic enhancement” purposes, “they 
appear to be far fewer and more speculative relative to [those 
enhancements that] might be possible in modifications of 
nDNA.”226 Based on these considerations, the committee 
“conclude[d] that it is ethically permissible to conduct clinical 
investigations of MRT, subject to certain conditions and 
principles[.]”227 
 Yet, clinical development of MRT may be precluded by the 
2017 rider.228 The 2017 rider precludes any “a human embryo is 
intentionally created or modified to include a heritable genetic 
modification.”229 In theory, heritable genetic modifications could 
be avoided by only transferring the nuclei from male zygotes.230 
Such an approach would be in line with the recommendations of 
the IOM report.231 However, a statement from Paul Richards, the 
spokesman for the FDA’s Center for Biologics Evaluation and 
Research, indicated that the agency deems the current rider to 
preclude any “human subject research utilizing genetic 
modification of embryos for the prevention of transmission of 
mitochondrial disease[.]”232 Thus, it appears that the rider must 
be amended before the FDA is willing to act on the IOM Report.233  
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 Without an exception to the 2017 rider, there is no path to 
clinical evaluation of MRT in the U.S. As a result, desperate 
parents may be forced to undergo the treatment off-shore, 
incurring added expense and potential danger. In fact, at least 
one such incident has already been reported: on April 6, 2016, the 
first baby was born using MRT in Mexico.234 The mother carried 
the gene signature for Leigh syndrome, a fatal disorder caused by 
mutations in the mitochondrial DNA.235 As MRT is not approved 
in the U.S. and might never be under the current language of the 
rider, the team of doctors decided to conduct the procedure in 
Mexico, where “there are no rules” against the procedure.236 The 
baby boy, now over one year old, was last known to be in good 
condition and will be monitored for any safety issues.237 If 
changes are not made to the law that accommodate treatment for 
select genetic diseases, these incidents are likely to continue in 
the future. 
 The IOM recommendations that allow selected 
applications of MRT significantly bolster the argument in favor of 
a limited exception that would allow FDA review of selected 
therapeutic uses of HGM. First, there is a similar rationale for 
the limited use of HGM as there is for the limited use of MRT. 
The IOM recommended the use of MRT for women who are 
otherwise at risk of transmitting a serious mtDNA disease, where 
the mutation’s pathogenicity is undisputed, and the clinical 
presentation of the disease is predicted to be severe.238 Similarly, 
the proposed exception would allow the use of HGM to treat 
“severe or life-threatening genetic diseases with a well-
established and specific genetic cause, when the end product is a 
wild-type gene and its use is restricted to patients who could not 
obtain equally effective treatment using other means.”239 The 
IOM noted the compelling purpose of MRT: to “satisfy the desire 
of a women seeking to have a genetically related child without the 
risk of passing on mtDNA disease[s.]”240 The purpose of 
therapeutic HGM is nearly identical: it would allow both men and 
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women who are afflicted with a genetic disease to have genetically 
related children without the risk of passing on nDNA diseases.  
 Second, the committee’s findings that “distinctions 
between modification of mtDNA and nDNA” warrant treatment 
of mtDNA diseases but not nDNA diseases are not persuasive.  
The report asserts that “the replacement of whole, intact, and 
naturally occurring mitochondrial genomes” is significantly 
different from approaches using “targeted genomic editing[.]”241 
However, some heterogeneity of mtDNA is observed during 
MRT,242 and targeted editing that resulted in a wild-type gene 
would also result in “naturally occurring” genes.243 In addition, 
targeted editing approaches may eventually lead to less genetic 
disruption than MRT because they only change parts selected 
genes, instead of entire blocs of mtDNA. 
 The report contends that unlike mtDNA, “traits that are 
carried in nDNA are those that in the public understanding 
constitute the core of genetic relatedness.”244 However, 
therapeutic HGM would only be approved by the FDA if there was 
little to no change of off-target editing.245 Thus, any clinically-
acceptable use of HGM should only result in de minimis 
alteration of the genome. Those genes on the nDNA that are 
associated with the core of genetic relatedness would be left 
unaltered by HGM, and the ancestral link between parent and 
child would be left intact.  
 The report also notes that mtDNA is limited in its effect on 
the organism and that any opportunities for enhancement using 
mtDNA “appear to be far fewer and more speculative relative to 
what might be possible in modifications of nDNA.”246 This 
distinction is predicated on an assumption that therapeutic HGM 
will necessarily lead to enhancement. Yet, the report itself 
unambiguously proposes that the MRT ought to be—and can be—
limited to therapeutic purposes.247 The same limitations can and 
should be imposed on the use of HGM. 
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 Finally, although therapeutic HGM would necessarily 
result in “heritable genetic mutations,” this alone is not enough 
to override the benefits that safe and effective HGM could offer. 
The IOM report indicated that the possibility of such heritable 
modifications should not necessarily preclude the use of MRT that 
resulted in inheritable mutations.248  The committee proposed 
that the FDA could consider extending the use of MRT to female 
embryos as long as safety and efficacy were established and the 
decision was consistent with public and scientific deliberations on 
acceptable limits of applicability.249 If such an approach is 
acceptable for the use of MRT, there is no reason why it should 
not also be adopted for the therapeutic application of HGM.  
 
d. Safety and Ethical Considerations 
 
 For some afflicted with a severe genetic disease, HGM may 
represent the only viable option for having healthy, genetically-
related children. Although these people may be relatively few in 
numbers, the harm that they suffer is real and their burden is 
immense. The current rider prevents them from accessing the one 
therapy that could help. It unnecessarily forces them to choose 
between rearing a child who will suffer a debilitating disease, or 
to forego parenthood in its entirety. Some may choose the latter 
option and for those people, the rider is a direct affront to their 
reproductive liberty.250 Others may be forced to engage in 
reproductive tourism, incurring great cost and health risk for 
themselves and their children. 
 Commentators have claimed that SCE can and will provide 
alternative treatments, obviating the need for HGM; however, 
SCE is not without its drawbacks. First, SCE can be extremely 
expensive: the cost of Glybera, the world’s first gene therapy, is 
about one million dollars.251 The treatment is so expensive that it 
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has only been used commercially for one patient.252 For many 
indications, HGM may prove to be a far cheaper and more 
effective option. Second, SCE is complicated and can be fraught 
with risk. It is well known that the retroviral vectors used to 
deliver the gene editing tools for SCE can lead to insertional 
mutagenesis, causing unintended genetic mutations in off-target 
and on-target cells.253 Side effects of SCE include acute 
inflammatory reactions,254 development of cancer,255 and 
death.256 While SCE requires genetic manipulation of millions of 
cells targeted to a specific organ, HGM requires successful gene 
editing only in single-celled zygotes.257 Although SCE is a 
promising technology for the treatment of many indications, it 
may not be an adequate substitute for HGM in all cases.  
 The proposed amendment would allow the development of 
complementary treatments that could have the potential to save 
lives and reduce the debilitating costs of healthcare. Moreover, if 
either PGD or SCE were found to be equally efficacious 
alternatives, the proposed amendment would preclude the FDA 
development of HGM in this field, because the exception is limited 
to situations “where the patients could not obtain equally 
effective treatment using other means.”258 
 As previously discussed, the most widely disseminated 
ethical opposition to the use of therapeutic HGM is that its use 
will start down a slippery slope towards enhancement. Such uses 
can continue to be prevented in exactly the same manner as they 
currently are: by the precluding FDA review of any application of 
HGM for enhancement. The proposed amendment does just that 
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by limiting the use of HGM to the “treatment of embryos where 
there is a substantial risk that the child will be born with a severe 
or life-threatening genetic disease, where the disease has a well-
established and specific genetic cause.”259 Limitations on the 
applications of therapies are ubiquitous in healthcare, including, 
for example, the IOM’s proposed limitation on the clinical 
development of MRT.260 
 
VII. CONCLUSION 
 
 Unless and until the U.S. adopts a comprehensive 
legislative scheme that regulates reproductive HGM, the current 
rider should be amended to permit the clinical development of 
HGM for a narrow subset of severe monogenic diseases.  The 
amendment proposed in this paper represents a balanced 
approach to HGM policy, reflecting the nuanced safety and ethical 
issues that were invoked by the legislature when crafting the 
rider in the first place. First, the proposed amendment limits the 
application of HGM only to those uses with the most compelling 
moral imperative: the treatment of severe genetic diseases. 
Second, the proposed amendment maintains the current ban on 
the use of HGM for enhancement, which has the highest danger 
for misuse.  Third, the amendment would only allow the gene 
editing that results in wild-type genes, alleviating any concern 
about introducing augmented genes into the gene pool. Finally, 
careful FDA scrutiny of any HGM protocol should be maintained 
throughout the entire process of clinical development, ensuring 
that HGM is only used if it is safe and efficacious.  
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